SCHEDULE: BlackRock Discloses 6.4% Stake in Sutro Biopharma

BlackRock, Inc. has reported a beneficial ownership of 6.4% in Sutro Biopharma, Inc. as of June 30, 2026.

Summary

• BlackRock, Inc. has filed a Schedule 13G, indicating a beneficial ownership of 1,065,366 shares of Sutro Biopharma, Inc. common stock.
• This ownership stake represents 6.4% of the class of securities.
• The filing is made by BlackRock, Inc. as a parent holding company, with specific reporting business units of BlackRock, Inc. and its subsidiaries and affiliates holding the shares.
• The date of the event requiring this filing is June 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates significant institutional interest from a major player like BlackRock, but provides no operational or financial performance data for Sutro Biopharma itself.

Positives

• BlackRock, a significant institutional investor, has taken a notable stake in Sutro Biopharma, potentially signaling confidence in the company's future prospects.
• The 6.4% ownership indicates substantial investment, which could lead to increased liquidity and market interest in Sutro Biopharma's stock.

Negatives

• The filing does not contain any negative financial results or operational challenges for Sutro Biopharma.
• No specific negative forward-looking statements are present in this filing.

Risks

• The filing does not explicitly mention any risks related to Sutro Biopharma's operations or market position.
• As a Schedule 13G filing, it primarily reports ownership and does not delve into company-specific operational risks.

Future Outlook

This filing is a Schedule 13G, which reports beneficial ownership and does not contain forward-looking statements or guidance from Sutro Biopharma.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by major asset managers like BlackRock in biotechnology firms often reflect a belief in the company's pipeline or market potential, especially in a sector characterized by innovation and high growth potential.

Stakeholder Impact

• Shareholders may view BlackRock's increased stake as a positive signal, potentially increasing investor confidence and stock liquidity.
• The investment by a large asset manager could attract further institutional interest in Sutro Biopharma.

Next Steps

• BlackRock will continue to monitor its investment in Sutro Biopharma.
• Sutro Biopharma will continue its business operations and strategic initiatives.

Key Dates

Recommendation

This filing is purely informational regarding ownership and does not provide performance data or strategic updates for Sutro Biopharma. Therefore, a 'hold' recommendation is appropriate, pending further company disclosures.

Keywords

Sutro Biopharma, BlackRock, Institutional Investor, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management